Literature DB >> 27851695

Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening.

Hongxue Luo1, Jerome L Belinson, Hui Du, Zhihong Liu, Lijie Zhang, Chun Wang, Xinfeng Qu, Robert G Pretorius, Ruifang Wu.   

Abstract

OBJECTIVE: The aim of the study was to evaluate the human papillomavirus (HPV) viral load combined with cytology as a secondary screening strategy after primary HPV screening.
MATERIALS AND METHODS: The data referring to direct Hybrid Capture 2 (HC2), cytology, and histology from Shenzhen Cervical Cancer Screening Trial II were re-analyzed to determine the correlation between viral load and cervical lesions. In addition, algorithms using different viral loads as cut points for immediate colposcopy plus cytology triage were compared with several recommended or controversial primary screening methods.
RESULTS: A total of 8,556 women with a mean age of 38.9 years were included in the analysis, of which 13.67% tested high-risk HPV positive with a prevalence of 2.72% for cervical intraepithelial neoplasia 2+ (CIN 2+) and 1.65% for CIN 3+. A significant correlation was observed between increasing relative light units/control (RLU/CO) values and worsening cervical lesions. The mean RLU/CO values for negative, CIN 1, CIN 2, CIN 3, and cancer were 6.86, 119.43, 410.90, 449.39, and 853.26, respectively. A larger proportion of HPV infections with relative high viral load (≥10 RLU/CO) were found in higher-grade lesions. The algorithm using 10 or greater RLU/CO as cut point for immediate colposcopy followed by triage cytology for the other positive (≥1 < 10 RLU/CO) had sensitivity of 93.13%/96.45% and specificity of 92.32%/91.44% for CIN 2+/3+, and the colposcopy referral rate was 10.00%.
CONCLUSIONS: Human papillomavirus viral load level is positively associated with cervical lesion grade. Ten relative light units/control or greater is a viable threshold for immediate colposcopy whereas 1 or greater or less than 10 RLU/CO is advised to reflex cytology for optimizing sensitivity and specificity, as well as referral rates.

Entities:  

Mesh:

Year:  2017        PMID: 27851695     DOI: 10.1097/LGT.0000000000000277

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  9 in total

1.  Verification of the association of the cycle threshold (Ct) values from HPV testing on Cobas4800 with the histologic grades of cervical lesions using data from two population-based cervical cancer screening trials.

Authors:  Yi Zhang; Hui Du; Aimin Xiao; Wei Zhang; Chun Wang; Xia Huang; Xinfeng Qu; Jianliu Wang; Ruifang Wu
Journal:  Infect Agent Cancer       Date:  2022-06-11       Impact factor: 3.698

2.  Human papillomavirus genotype prevalence in the women of Shanghai, China and its association with the severity of cervical neoplasia.

Authors:  Jingbo Wu; Xiaojing Li; Xiuping Liu; Zuhua Gao
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

3.  Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia.

Authors:  Clementina Elvezia Cocuzza; Marianna Martinelli; Federica Sina; Andrea Piana; Giovanni Sotgiu; Tiziana Dell'Anna; Rosario Musumeci
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

4.  Composite Analysis of the Virome and Bacteriome of HIV/HPV Co-Infected Women Reveals Proxies for Immunodeficiency.

Authors:  Juliana D Siqueira; Gislaine Curty; Deng Xutao; Cristina B Hofer; Elizabeth S Machado; Héctor N Seuánez; Marcelo A Soares; Eric Delwart; Esmeralda A Soares
Journal:  Viruses       Date:  2019-05-07       Impact factor: 5.048

5.  HPV viral load in self-collected vaginal fluid samples as predictor for presence of cervical intraepithelial neoplasia.

Authors:  Malin Berggrund; Inger Gustavsson; Riina Aarnio; Julia Hedlund-Lindberg; Karin Sanner; Ingrid Wikström; Stefan Enroth; Matts Olovsson; Ulf Gyllensten
Journal:  Virol J       Date:  2019-11-27       Impact factor: 4.099

6.  Analysis of influencing factors of viral load in patients with high-risk human papillomavirus.

Authors:  Xuerong Lu; Tiantian Wang; Youzhong Zhang; Yuzhen Liu
Journal:  Virol J       Date:  2021-01-06       Impact factor: 4.099

7.  Association of Relative Telomere Length and Risk of High Human Papillomavirus Load in Cervical Epithelial Cells.

Authors:  A H Albosale; E V Mashkina
Journal:  Balkan J Med Genet       Date:  2022-06-05       Impact factor: 0.810

8.  Cervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins.

Authors:  Erdem Sahin; Yusuf Madendag; Mefkure Eraslan Sahin; Ilknur Col Madendag; Gokhan Acmaz; Cıgdem Karakukcu; Hatice Karaman; Iptisam Ipek Muderris
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

9.  Evidence of No Association Between Human Papillomavirus and Breast Cancer.

Authors:  Sara Bønløkke; Jan Blaakær; Torben Steiniche; Estrid Høgdall; Steffen Grann Jensen; Anne Hammer; Eva Balslev; Mikael Lenz Strube; Helle Knakkergaard; Suzan Lenz
Journal:  Front Oncol       Date:  2018-06-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.